Publications by authors named "Sophie Ottaviano"
Lancet Glob Health
December 2023
Article Synopsis
- People who inject drugs are heavily impacted by HIV and hepatitis C virus infections, but there is a lack of global data on their testing and treatment coverage, prompting a systematic review to gather this information.
- The review involved searching various databases for studies published between January 2017 and April 2022, focusing on the proportions of people who inject drugs receiving testing and treatment for HIV and HCV across different countries.
- The findings revealed that of the data analyzed, about 48.8% of people who inject drugs were recently tested for HIV antibodies and 47.1% had ever been tested for HCV antibodies, with some countries showing notably high testing coverage.
Lancet Glob Health
May 2023
Article Synopsis
- A systematic review updated global coverage estimates of essential harm reduction services for people who inject drugs (PWID), including needle and syringe exchange programs (NSPs) and opioid agonist treatment (OAT), based on studies published from 2017 to 2022.*
-
- Key findings revealed that 90 countries offer OAT and 94 countries provide NSPs, benefiting a significant percentage of the PWID population, but very few countries (only five) achieve high coverage of both services.*
-
- The study highlighted that other harm reduction initiatives, like take-home naloxone programs and supervised consumption facilities, were less commonly implemented, with varying coverage levels observed across different countries.*
Lancet Glob Health
May 2023
Article Synopsis
- The study conducted a global systematic review to assess the prevalence of injecting drug use (IDU) and its associated harms, including infections like HIV and hepatitis, as well as overdose.
- Researchers analyzed a vast number of reports published from 2017 to 2022 to gather data on socio-demographic characteristics, risk exposures, and health outcomes related to IDU.
- The findings revealed that 14.8 million individuals aged 15-64 worldwide inject drugs, with a notable gender disparity in the prevalence of IDU, as well as unique risks faced by women and transgender individuals.
